Previous 10 | Next 10 |
Adamis Pharmaceuticals ( ADMP ) received a Complete Response Letter from the FDA in regards to the company's ZIMHI product candidate. Following the press release, the share price was decimated and is now trading around $0.60 a share. This leaves ADMP with a tough decision about how they are ...
Gainers: JanOne (NASDAQ: JAN ) +103% . More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
CymaBay Therapeutics (NASDAQ: CBAY ) -75% on halting trial of seladelpar. More news on: CymaBay Therapeutics, Inc., Adamis Pharmaceuticals Corporation, La Jolla Pharmaceutical Company, Stocks on the move, Read more ...
The FDA rejects Adamis Pharmaceuticals (NASDAQ: ADMP ) opioid overdose treatment. More news on: Adamis Pharmaceuticals Corporation, Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of U.S. markets on November 22 nd , it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...
Adamis Pharmaceuticals ( ADMP ) recently reported their Q3 earnings with a slight miss on EPS and revenue. The company reported ~$5.9M in revenue, which is a 54% increase from Q3 of 2018. In addition, the company discussed pipeline progress, commercial partnership updates, manufacturing upgr...
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of Community Use Naloxone Formulations for Acute Treatment of Opioid Overdose...
Adamis Pharmaceuticals Corp (ADMP) Q3 2019 Earnings Conference Call November 12, 2019, 17:00 ET Company Participants Dennis Carlo - President, CEO & Director Robert Hopkins - SVP, Finance, CFO & Secretary Ronald Moss - Chief Medical Officer David Marguglio - SVP, Chief ...
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q3 GAAP EPS of -$0.12 misses by $0.02 . More news on: Adamis Pharmaceuticals Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2019 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Adamis Pharmaceuticals Corporation Company Name:
ADMP Stock Symbol:
NASDAQ Market:
Adamis Pharmaceuticals Corporation Website:
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing sm...
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 ...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in...